Immunovant, Inc. IMVT
35.05 USD -1.99 (-5.37%)
At closeNov 12, 2026, 4:00 PM EST
34.80 -0.25 -0.71%
After hours · Nov 12, 4:00 PM ET
34.86 Day range 36.92
21.86 52-week range 45.42
- YTD
- +37.88%
- 1 year
- +49.53%
Benzinga news
benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $30 to $33.
benzinga.com Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.
benzinga.com Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant reports positive trial results for IMVT-1402 in rheumatoid arthritis and plans FDA discussions on a registrational pathway.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com Immunovant Q1 2027 Earnings Call: Complete Transcript Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
benzinga.com Immunovant Ends Autoimmune Skin Disorder Program Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
benzinga.com Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus…
benzinga.com Immunovant Q1 2027 Earnings Call: Complete Transcript On Thursday, Immunovant (NASDAQ:IMVT) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs.…
benzinga.com Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71)…
benzinga.com JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50 JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.- benzinga.com Citigroup Maintains Buy on Immunovant, Raises Price Target to $61 Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.
benzinga.com CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sandler increased price target for TRV, and more.- benzinga.com Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62 Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.
benzinga.com Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30 Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raises the price target from $23 to $30.
benzinga.com These Analysts Increase Their Forecasts On Immunovant After Q4 Results Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
benzinga.com B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43 B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $32 to $43.
benzinga.com HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40 HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $35 to $40.
benzinga.com Immunovant Stock Surges Despite Disappointing Earnings Miss Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Down 5%; Lowe's Posts Upbeat Earnings US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe's Companies reported upbeat earnings.
benzinga.com TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 20, 2026 - benzinga.com Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of…
benzinga.com Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.- benzinga.com Market-Moving News for April 2nd GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in discussions to acquire the company. IMVT: -17% | Immunovant shares are trading lower after the company
benzinga.com Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo Energy SA, Semilux International Ltd, Visionary Holdings Inc, and more. Losers are PMGC Holdings…- benzinga.com Earnings Scheduled For February 6, 2026
benzinga.com Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday 
benzinga.com Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
- benzinga.com Why Sharps Technology Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.
benzinga.com Earnings Scheduled For June 8, 2022 Companies Reporting Before The Bell • Immunovant (NASDAQ:IMVT) is expected to report earnings for its fourth quarter.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 435 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 431 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 109 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 209 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 9, 2021 Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 185 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 180 companies set new 52-week highs.